RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
NeuBase Therapeutics Stock

NeuBase Therapeutics P/S 2024

NeuBase Therapeutics P/S

0

Ticker

NBSE

ISIN

US64132K1025

WKN

A2PNYF

As of Nov 9, 2024, NeuBase Therapeutics's P/S ratio stood at 0, a 0% change from the 0 P/S ratio recorded in the previous year.

The NeuBase Therapeutics P/S history

NeuBase Therapeutics Aktienanalyse

What does NeuBase Therapeutics do?

NeuBase Therapeutics Inc. is an advanced biotechnology company focused on developing a new class of therapeutics based on proprietary platform technology. The company aims to develop an improved treatment option for people with genetically inherited diseases, including cancer. NeuBase's business model is designed to generate additional revenue through the sale of licenses for its patented platform technology. The company also has its own pipeline of therapeutics, allowing it to directly benefit from product sales. The various divisions of the company focus on different application areas, including rare diseases, cancer therapeutics, and genetic improvements for crops. The NeuBase platform's ability to address targeted gene modification issues in the development of therapeutic proteins is particularly impressive. This system allows for precise molecular level edits of genes, leading to improved efficacy and safety. One example of a NeuBase product is NB3001, used for treating genetic targeting-specific neurodegenerative diseases. Overall, NeuBase is an exciting biotech company with an innovative platform technology targeting genetic diseases and cancer. It has an impressive pipeline of therapeutics and the potential to become a leading company in the genomics-based therapy industry. NeuBase Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding NeuBase Therapeutics's P/S Ratio

NeuBase Therapeutics's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing NeuBase Therapeutics's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating NeuBase Therapeutics's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in NeuBase Therapeutics’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about NeuBase Therapeutics stock

What is the price-to-earnings ratio of NeuBase Therapeutics?

The price-earnings ratio of NeuBase Therapeutics is currently 0.

How has the price-earnings ratio of NeuBase Therapeutics changed compared to last year?

The price-to-earnings ratio of NeuBase Therapeutics has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of NeuBase Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of NeuBase Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of NeuBase Therapeutics affect the company?

An increase in the price-earnings ratio of NeuBase Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of NeuBase Therapeutics affect the company?

A decrease in the price-earnings ratio of NeuBase Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of NeuBase Therapeutics?

Some factors that influence the price-earnings ratio of NeuBase Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does NeuBase Therapeutics pay?

Over the past 12 months, NeuBase Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, NeuBase Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of NeuBase Therapeutics?

The current dividend yield of NeuBase Therapeutics is .

When does NeuBase Therapeutics pay dividends?

NeuBase Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of NeuBase Therapeutics?

NeuBase Therapeutics paid dividends every year for the past 0 years.

What is the dividend of NeuBase Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is NeuBase Therapeutics located?

NeuBase Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von NeuBase Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of NeuBase Therapeutics from 11/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/9/2024.

When did NeuBase Therapeutics pay the last dividend?

The last dividend was paid out on 11/9/2024.

What was the dividend of NeuBase Therapeutics in the year 2023?

In the year 2023, NeuBase Therapeutics distributed 0 USD as dividends.

In which currency does NeuBase Therapeutics pay out the dividend?

The dividends of NeuBase Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von NeuBase Therapeutics

Our stock analysis for NeuBase Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of NeuBase Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.